Hexarelin vs Ipamorelin
Both are growth hormone releasing peptides (GHRPs) that stimulate GH via the ghrelin receptor, but differ significantly in selectivity and side effect profiles. Ipamorelin is more selective; Hexarelin is more potent.
Last updated: 2026-02-04
Hexarelin and Ipamorelin are both synthetic growth hormone releasing peptides (GHRPs) that stimulate growth hormone (GH) release by activating the ghrelin receptor (GHS-R1a) in the pituitary gland. Despite sharing this fundamental mechanism, they represent different approaches to GH stimulation with distinct pharmacological profiles.
Hexarelin, developed in the 1990s, was one of the first potent synthetic GH secretagogues and remains one of the most powerful GHRPs studied. Ipamorelin, developed later, was specifically designed for selectivity—stimulating GH release without significantly affecting cortisol, prolactin, or appetite.
Understanding these differences is critical for researchers studying growth hormone physiology and for clinicians evaluating potential applications. This comparison examines the mechanisms, research evidence, and key distinguishing features of these two important GHRPs.
**Important Note:** Neither Hexarelin nor Ipamorelin is approved for therapeutic use by the MHRA, EMA, or FDA. Both are prohibited by WADA in competitive sport. This comparison is for educational purposes only.
Quick Comparison Table
| Category | Hexarelin | Ipamorelin |
|---|---|---|
| Peptide Class | Growth Hormone Releasing Peptide (GHRP) | Growth Hormone Releasing Peptide (GHRP) |
| Amino Acids | 6 amino acids (hexapeptide) | 5 amino acids (pentapeptide) |
| GH Release Potency | Very high—one of the most potent GHRPs | Moderate—reliable but gentler GH release |
| Cortisol Effect | Significant increase at higher doses | Minimal to no effect on cortisol |
| Prolactin Effect | Moderate increase possible | Minimal to no effect on prolactin |
| Appetite Stimulation | Moderate ghrelin-like appetite increase | Minimal appetite stimulation |
| Selectivity | Less selective—affects multiple hormones | Highly selective for GH release |
| Cardiac Research | Cardioprotective effects studied | Limited cardiac-specific research |
| Desensitisation Risk | Higher risk with chronic use | Lower risk—may maintain sensitivity |
| Research Status | Extensive preclinical, some clinical data | Phase II trials completed (discontinued) |
Mechanism of Action: How They Differ
Hexarelin
Hexarelin Mechanism:
Hexarelin is a synthetic hexapeptide that potently stimulates growth hormone release through multiple pathways:
1. GHS-R1a Receptor Activation Hexarelin binds to and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the ghrelin receptor, on pituitary somatotrophs. This triggers intracellular calcium release and GH secretion.
2. Non-Selective Receptor Effects Unlike more modern GHRPs, Hexarelin has broader receptor interactions: - Affects hypothalamic pathways beyond GH regulation - Stimulates ACTH release, leading to cortisol elevation - Can increase prolactin levels - Activates appetite-stimulating pathways
3. Potent GH Pulse Generation Hexarelin produces one of the largest GH releases of any GHRP, typically generating plasma GH increases of 2-3 fold higher than Ipamorelin at equivalent doses.
4. Cardioprotective Signalling Unique among GHRPs, Hexarelin has demonstrated direct cardiac effects through receptor subtypes in heart tissue, independent of GH release: - Protection against ischemia-reperfusion injury - Calcium handling improvement in cardiomyocytes - Anti-apoptotic effects in cardiac cells
5. Desensitisation Profile Chronic Hexarelin use may lead to receptor desensitisation, requiring cycling protocols in research settings.
Ipamorelin
Ipamorelin Mechanism:
Ipamorelin was specifically engineered for selectivity, representing a "clean" GHRP with minimal off-target effects:
1. Selective GHS-R1a Activation Ipamorelin activates the ghrelin receptor with high specificity, triggering GH release without significantly engaging other receptor systems or hormonal pathways.
2. Preserved Pulsatility Unlike some GH secretagogues that cause sustained GH elevation, Ipamorelin stimulates physiological-style pulsatile release, which may better preserve hypothalamic-pituitary feedback.
3. Hormonal Selectivity Key distinguishing feature—Ipamorelin does NOT significantly affect: - Cortisol levels (no ACTH stimulation) - Prolactin levels - Appetite/hunger signalling - Aldosterone or thyroid hormones
4. Gentle Dose-Response Ipamorelin shows a more linear, predictable dose-response curve with a wider therapeutic window before side effects emerge.
5. Synergy with GHRH Ipamorelin is frequently combined with GHRH analogues (CJC-1295, Sermorelin) for synergistic GH release. The "push-pull" mechanism amplifies GH output while maintaining selectivity.
6. Reduced Desensitisation Research suggests Ipamorelin may cause less receptor desensitisation than older GHRPs, potentially allowing for more sustained use protocols.
Clinical Trial Evidence
Hexarelin Clinical Studies
Participants: 18 healthy young adults
Duration: Acute dosing crossover
Hexarelin produced peak GH levels 2-3x higher than equivalent doses of GHRP-6. Dose-response confirmed up to saturation at ~1mcg/kg.
Established Hexarelin as most potent GHRP; defined saturation dose principle
Participants: Rat myocardial infarction model
Duration: 4 weeks post-MI
Hexarelin reduced infarct size by 40% and improved left ventricular function independent of GH release via direct cardiac receptor effects.
Landmark evidence for cardioprotective mechanism unique among GHRPs
Participants: 24 healthy volunteers
Duration: Single-dose analysis
GH release accompanied by 25-50% cortisol elevation and 20-30% prolactin increase. ACTH stimulation confirmed.
Defined less selective hormonal profile; informed development of newer GHRPs
Participants: 28 patients with ischemic heart disease
Duration: 12 weeks
Improved cardiac output and exercise tolerance in some participants. Direct cardiac effects observed independent of GH-mediated pathways.
Advanced cardiac application research; supported cardioprotective mechanism
Participants: 16 healthy adults
Duration: 6 weeks continuous dosing
GH response declined by ~40% after 4-6 weeks of continuous administration. Recommended cycling protocols to maintain efficacy.
Established need for cycling; informed research protocol design
Ipamorelin Clinical Studies
Participants: Multiple subject groups and animal models
Duration: Acute and chronic studies
Ipamorelin achieved equipotent GH release to GHRP-6 with no significant ACTH, cortisol, or prolactin elevation.
Foundational study establishing Ipamorelin's unique selectivity profile
Participants: 186 patients post-bowel resection
Duration: 7 days
Ipamorelin showed trend toward faster GI recovery but did not meet primary endpoint. Excellent safety profile confirmed.
Largest human safety trial for Ipamorelin; tolerability validated
Participants: 36 healthy volunteers
Duration: Acute dosing crossover
Head-to-head comparison confirmed Ipamorelin achieved GH release comparable to GHRP-2/GHRP-6 with significantly less cortisol and prolactin elevation.
Quantified selectivity advantage; validated 'cleanest GHRP' designation
Participants: 48 healthy adults
Duration: 8 weeks
Chronic Ipamorelin administration showed sustained GH-releasing efficacy without tachyphylaxis or significant adverse events.
Supported safety of extended research protocols without cycling
Participants: 24 elderly subjects (65-80 years)
Duration: Single-dose assessment
Ipamorelin maintained robust GH-releasing efficacy in elderly subjects with 3-4x baseline GH increases.
Demonstrated preserved efficacy in age-related GH decline population
Benefits Comparison
Hexarelin Unique Benefits
- Most potent GH release of any GHRP studied
- Direct cardioprotective effects independent of GH
- Ischemia-reperfusion injury protection researched
- Extensive research history since 1990s
- Potential for cardiac muscle preservation
- Strong acute GH pulse for research applications
- Anti-apoptotic effects in cardiac tissue
Shared Benefits
- Stimulate pulsatile growth hormone release
- Activate ghrelin receptor (GHS-R1a)
- May enhance sleep quality when dosed pre-bed
- Support recovery and tissue repair research
- Synergise with GHRH analogues
- Short half-life allows flexible dosing
- Generally well-tolerated in research
Ipamorelin Unique Benefits
- Highly selective—minimal hormonal disruption
- No cortisol elevation (better for sleep/stress)
- No prolactin increase (important for certain populations)
- Minimal appetite stimulation (better for fat loss research)
- Lower desensitisation risk
- Wider therapeutic window
- Better tolerated in research settings
- Preferred for long-term protocols
Research & Evidence
Hexarelin Research
Hexarelin Research Evidence:
Hexarelin has an extensive research history dating to the early 1990s, with notable clinical and preclinical findings:
GH Secretion Studies: - Consistently demonstrated potent GH release in human studies - Dose-dependent responses well-characterised - Comparative studies show superior GH output vs other GHRPs - Elderly subjects respond with preserved GH release
Cardiac Research: - Phase II trials investigated cardioprotective effects post-MI - Animal studies show reduced infarct size and improved cardiac function - Direct cardiac receptor effects documented - Potential for heart failure applications explored
Other Research Areas: - Effects on body composition and lean mass - Bone metabolism and density effects - Neuroprotective properties investigated - Growth hormone deficiency applications studied
Limitations: - Development discontinued by Pharmacia - Cortisol/prolactin effects limit clinical applicability - Desensitisation with chronic dosing observed - No approved clinical indication
Ipamorelin Research
Ipamorelin Research Evidence:
Ipamorelin was developed by Novo Nordisk and underwent significant clinical development:
Phase I/II Clinical Trials: - Well-tolerated GH release documented in healthy volunteers - Dose-response relationships established - Confirmed selectivity for GH without cortisol/prolactin effects - Studied for postoperative ileus (gut motility)
Selectivity Studies: - Multiple studies confirm minimal ACTH/cortisol stimulation - Prolactin levels unaffected at therapeutic doses - No significant impact on appetite compared to placebo - Thyroid and aldosterone parameters stable
Postoperative Applications: - Phase II trials for accelerating gut recovery after surgery - Mixed results led to development discontinuation - Safety profile was acceptable
Body Composition Research: - Effects on lean mass and fat mass studied - Sleep and recovery effects investigated - Popular in research settings due to tolerability
Limitations: - Clinical development discontinued - Less potent than Hexarelin for pure GH output - Limited cardiac-specific research - No approved clinical indication
Head-to-Head Analysis
Direct Comparison:
No head-to-head clinical trials directly compare Hexarelin and Ipamorelin. However, comparative analysis of separate studies allows several conclusions:
GH Release: Hexarelin produces significantly higher peak GH levels than Ipamorelin at equivalent doses—approximately 2-3 times greater GH output. This makes Hexarelin more potent but also less selective.
Hormonal Impact: The key differentiator is selectivity. Hexarelin increases cortisol by 20-50% and can elevate prolactin, while Ipamorelin causes no statistically significant changes in either hormone.
Tolerability: Ipamorelin is generally better tolerated, with fewer side effects related to cortisol elevation (anxiety, sleep disruption) or prolactin (gynecomastia risk in susceptible individuals).
Clinical Progression: Neither peptide achieved regulatory approval. Hexarelin's broader hormonal effects and Ipamorelin's modest gut motility results led to discontinued development for both.
Research Community Preference: Ipamorelin has become the preferred GHRP in research protocols requiring GH stimulation without confounding hormonal variables. Hexarelin remains relevant for cardiac research applications.
Protocol Comparison
Hexarelin Protocol
Hexarelin Research Protocols (For Reference Only):
Typical Research Parameters: - Doses: 1-2 mcg/kg body weight - Frequency: 1-3 times daily - Administration: Subcutaneous injection - Timing: Often pre-training or pre-bed - Cycling: Commonly cycled 4-8 weeks on, 4 weeks off
Considerations: - Higher potency requires careful dose titration - Desensitisation risk necessitates cycling - Cortisol elevation may be problematic pre-bed - Fasted administration typically preferred - Monitor for appetite changes
Combination Approaches: - May be combined with GHRH analogues - Some protocols alternate with other GHRPs - "Saturation dose" concept: ~1 mcg/kg
Ipamorelin Protocol
Ipamorelin Research Protocols (For Reference Only):
Typical Research Parameters: - Doses: 100-300 mcg per administration - Frequency: 1-3 times daily - Administration: Subcutaneous injection - Timing: Pre-bed most common for sleep/recovery research - Cycling: Often used continuously without cycling
Considerations: - More forgiving dose-response curve - Minimal cortisol effect makes pre-bed dosing ideal - Fasted state optimises GH response - Can be used for extended periods - Combine with GHRH for enhanced response
Combination Approaches: - CJC-1295 (no DAC) + Ipamorelin is popular combination - Sermorelin + Ipamorelin studied - Rarely combined with other GHRPs - "Saturation dose" less relevant due to selectivity
Combined Use
Combining Hexarelin and Ipamorelin:
Combining two GHRPs that both work through the ghrelin receptor is unusual and generally not supported by research protocols. Since both compete for the same receptor, combination is unlikely to provide additive benefits.
More Common Research Approaches:
1. GHRP + GHRH Combination: Rather than combining two GHRPs, researchers typically combine one GHRP with a GHRH analogue: - Ipamorelin + CJC-1295 (most popular) - Hexarelin + Sermorelin (less common)
This "push-pull" approach maximises GH release through complementary pathways.
2. Rotating GHRPs: Some protocols rotate between different GHRPs to theoretically reduce desensitisation, though evidence for this is limited.
3. Preference for Ipamorelin: Given its superior selectivity and tolerability, Ipamorelin is generally preferred unless cardiac-specific research requires Hexarelin's direct cardioprotective effects.
Note: All such protocols are experimental and not validated for therapeutic use.
Safety Profiles
Hexarelin Safety
Hexarelin Safety Profile:
Common Effects: - Injection site reactions (redness, swelling) - Flushing and warmth following injection - Water retention in some subjects - Increased appetite (ghrelin pathway activation) - Transient dizziness or light-headedness
Hormonal Effects: - Cortisol elevation (20-50% increase) - Potential anxiety or restlessness from cortisol - Prolactin increase possible - May affect sleep if dosed late (cortisol effect)
Concerning Observations: - Receptor desensitisation with chronic use - Unknown long-term effects - Cardiac effects require monitoring - WADA prohibited substance
Contraindications (Theoretical): - Active malignancy or cancer history - Cardiovascular disease (despite cardioprotective research) - Diabetes (GH affects glucose metabolism) - Pregnancy/breastfeeding - Children/adolescents (except under research protocols)
Ipamorelin Safety
Ipamorelin Safety Profile:
Common Effects: - Injection site reactions (typically mild) - Transient flushing post-injection - Mild water retention possible - Head rush or light-headedness (uncommon)
Notably Absent: - No significant cortisol elevation - No prolactin increase - Minimal appetite stimulation - No ACTH effects
This selectivity profile makes Ipamorelin: - Better tolerated overall - Suitable for pre-bed administration - Lower risk for hormone-sensitive conditions - Preferred for research requiring hormonal stability
Concerning Observations: - Long-term effects unknown - Theoretical cancer risk with any GH stimulation - WADA prohibited substance - Not approved for any clinical use
Contraindications (Theoretical): - Active malignancy or cancer history - Uncontrolled diabetes - Pregnancy/breastfeeding - Children/adolescents - Those with pituitary abnormalities
The Verdict: When to Choose Which?
Choose Hexarelin When:
- Maximum GH release potency is the research goal
- Cardiac research applications are the focus
- Short-term, high-output protocols are designed
- Cardioprotective effects are being investigated
- Subject can tolerate cortisol/prolactin effects
- Cycling protocols can be implemented
Choose Ipamorelin When:
- Clean GH release without hormonal disruption is needed
- Pre-bed dosing for sleep/recovery research
- Long-term protocols without desensitisation
- Research requires stable cortisol/prolactin baselines
- Subject tolerability is prioritised
- Combination with GHRH analogues is planned
- Fat loss research where appetite stimulation is undesirable
Consider Combining When:
- Combination of two GHRPs is generally not recommended
- Both compete for the same ghrelin receptor
- Instead: combine one GHRP with a GHRH analogue
- Ipamorelin + CJC-1295 is the preferred combination
- Hexarelin + Sermorelin for cardiac-focused protocols
Frequently Asked Questions
Conclusion
Hexarelin and Ipamorelin represent different philosophies in GHRP development. Hexarelin, an earlier compound, prioritised potent GH release, achieving impressive output but at the cost of hormonal selectivity. Ipamorelin, developed with selectivity as the primary goal, offers a "cleaner" profile that has made it the preferred GHRP in modern research protocols.
Key Takeaways:
Choose Hexarelin when: - Maximum GH output is the research objective - Cardiac research applications are the focus - Short-term, cycling protocols are acceptable - Cortisol and prolactin effects are tolerable
Choose Ipamorelin when: - Selective GH release is required - Pre-bed dosing for sleep/recovery research - Long-term protocols are planned - Combination with GHRH analogues is intended - Hormonal stability is important
Neither is Approved: Both peptides remain research compounds with no regulatory approval for therapeutic use. They are prohibited by WADA in competitive sport. Any use outside research settings carries unknown risks.
*Always consult accredited suppliers and qualified healthcare professionals in your jurisdiction.*
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Hexarelin nor Ipamorelin is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.